StreetAlpha.app
Home › Stocks › TVTX

Travere Therapeutics, Inc. (TVTX)

Healthcare
$51.10
▲ +2.82%
LAST CLOSE · NOV 17

Travere Therapeutics is a San Diego biopharmaceutical company that develops and sells treatments for rare kidney and metabolic diseases. It last closed at $51.10 on Nov 17, up 2.82% on the day. TVTX last reported earnings on Mon, Nov 2, 2026. The average 12-month price target from 6 analysts is $74.33 (+45.5% from the last close), with a high of $86.00 and a low of $67.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell). In the past 30 days there were 3 dark pool prints totaling $5.1M, the largest $2.6M.

AI Auto Pilots
Is TVTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$651.0M
+49.4% vs a year ago
Net income
−$121.5M
−18.7% margin
EPS (diluted)
−$1.30
Gross margin
98.5%
$641.5M gross profit
Valuation
Market cap
$4.9B
96.0M shares
P/E
–
No P/E while losing money
Price to sales
7.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$123.5M
At Sep 30
Shareholder equity
$22.6M
Shares outstanding
96.0M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $131.8M$131.8MFY2021FY2022: $109.5M$109.5MFY2022FY2023: $145.2M$145.2MFY2023FY2024: $233.2M$233.2MFY2024FY2025: $490.7M$490.7MFY2025

From TVTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Last report
Nov 2
2026 · After the close (AMC)
Reported EPS
-$0.55
vs -$0.25 est. · miss
Year-ago EPS
$0.59
Same quarter last year
Options-implied move
±10.1%
Priced in before that report
Analyst consensus
Strong Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
6firms
6 Buy0 Hold0 Sell
Each firm's latest rating on TVTX in the past 90 days
Average 12-month target
$74.33
▲ 45.5% upside

Based on 6 analysts who set a price target on TVTX in the past 90 days. The average target is $74.33, with a high of $86.00 and a low of $67.00, compared with the last close of $51.10.

Low $67.00Avg $74.33High $86.00
Blue marker: last close $51.10
Highest target$86.00
Average target$74.33
Lowest target$67.00
Latest rating changes
JP MorganMaintained
Nov 7Buy$86
Leerink PartnersMaintained
Nov 5Buy$67
Canaccord GenuityTarget raised
Nov 4Buy$70 → $72
GuggenheimTarget lowered
Nov 4Buy$89 → $78
GuggenheimTarget raised
Sep 24Buy$75 → $89
DateFirmActionRatingPrice target
Nov 7JP MorganMaintainedBuy$86
Nov 5Leerink PartnersMaintainedBuy$67
Nov 4Canaccord GenuityTarget raisedBuy$70 → $72
Nov 4GuggenheimTarget loweredBuy$89 → $78
Sep 24GuggenheimTarget raisedBuy$75 → $89
Loading…

Technical Analysis

TVTX · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock sits between its 20 and 50 day averages. It is 6% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 47). The nearest support is the 20 day average at $50.80, and the nearest resistance the Pivot R1 at $52.10.

Short trendBearish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 4.8%/day
Key levels
$68.7352 week high+34.5%
$57.86100 day average+13.2%
$55.3250 day average+8.3%
$52.52Swing high (Nov 12)+2.8%
$52.10Pivot R1+2.0%
$51.10Last close
$50.8020 day average−0.6%
$50.18Pivot−1.8%
$49.46Swing low (Oct 16)−3.2%
$49.17Pivot S1−3.8%
$47.87200 day average−6.3%
$22.5952 week low−55.8%
Indicators
RSI (14)46.63Middle of its rangeNeutral
MACD-1.02Above its signal lineBullish
Stochastic67.1Middle of its rangeNeutral
ADX (14)15.7No clear trend
Williams %R-25.7Oversold below −80, overbought above −20Neutral
CCI (20)-46.2Oversold below −100, overbought above 100Neutral
Rate of change+3.4%Change over 10 sessionsBullish
ATR (14)$2.44Typical daily range, 4.8% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Above
What happened before, for TVTX

What happened before

See how TVTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow TVTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How TVTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in TVTX in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$5.1M
Largest print
$2.6M
Loading…

TVTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲211 buying vs 142 selling
  • ▲Held by funds +5.9 pts
  • ▲Funds holding +26
  • ▼Superinvestors: 1 added, 3 cut
  • ▼Put/call 0.01 to 0.03
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding353327+8.0%
In funds' top 101311+18.2%
Held by funds121.6%115.7%+5.9 pts
New / increased65 / 14693 / 120−0.9%
Reduced / sold out105 / 3786 / 31+21.4%
Put/call ratio0.030.01+167.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TVTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TVTX is in one of them and how their past TVTX trades turned out.

TVTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TVTX in an article yet. Here's the latest on the wider market.

About Travere Therapeutics

Travere Therapeutics is a biopharmaceutical company based in San Diego, California. It develops and sells treatments for people with rare kidney and metabolic diseases. Its approved product, FILSPARI, is indicated to slow kidney function decline in adults with a rare kidney disease called primary IgAN. The company is also seeking approval of FILSPARI for another kidney condition, FSGS, and is developing pegtibatinase for HCU, a genetic metabolic disorder.

Headquarters
San Diego, CA